Preparation Technique Affects Recipient Immune Targeting of Autologous Mesenchymal Stem Cells.
Authors: Rowland Aileen L, Burns Madison E, Levine Gwendolyn J, Watts Ashlee E
Journal: Frontiers in veterinary science
Summary
# Editorial Summary: Mesenchymal Stem Cell Preparation and Immune Compatibility in Horses Fetal bovine serum (FBS) has become standard in mesenchymal stem cell (MSC) culture for both research and clinical use, yet its immunological consequences in the recipient have remained largely unexplored—particularly problematic in horses, which develop high anti-bovine antibody titres through routine vaccination protocols. Rowland and colleagues tested whether these pre-existing antibodies compromise autologous MSC efficacy by comparing synovial MSC preparations cultured with and without FBS, measuring recipient immune activation, MSC survival, and functional outcomes in an equine model. FBS-prepared cells triggered significantly greater post-injection inflammation and antibody-mediated cytotoxicity, resulting in reduced synovial MSC concentrations and heightened lipopolysaccharide-induced pain responses compared to FBS-free preparations—a clear demonstration of reduced therapeutic efficacy linked directly to preparation technique. These findings suggest that current clinical MSC products authorised internationally using FBS protocols may underperform due to pre-existing immune targeting, whilst highlighting the importance of reviewing preparation methods across both research literature and commercial therapeutics. For equine practitioners utilising or considering MSC therapies, this work underscores the need to verify culture protocols and raises questions about the reliability of efficacy data derived from FBS-prepared cells in species with naturally high anti-bovine immunity.
Read the full abstract on PubMed
Practical Takeaways
- •When selecting MSC products or preparations for therapeutic use, verify that FBS was NOT used in cell culture—this significantly compromises efficacy in vaccinated horses
- •Previously published efficacy data on FBS-prepared MSCs should be interpreted cautiously, as reduced cell viability and higher inflammatory responses may underestimate true therapeutic potential of optimized preparations
- •If considering MSC therapy for joint or soft-tissue injuries, ensure the product uses FBS-free preparation protocols to maximize cell survival and therapeutic outcome
Key Findings
- •MSCs prepared with FBS induced post-injection inflammation and antibody-mediated cytotoxicity compared to FBS-free preparation
- •Synovial MSC concentrations were reduced when FBS was used in preparation
- •Horses receiving FBS-prepared MSCs demonstrated higher LPS-induced pain responses, indicating reduced therapeutic efficacy
- •Anti-bovine antibody titers in horses (universally high due to vaccination) are responsible for immune targeting of FBS-exposed MSCs